Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 10 of 10
Full-Text Articles in Medicine and Health Sciences
Accelerated Fractionation In Inoperable Non-Small Cell Lung Cancer. A Phase I/Ii Study, Edward Yu, Luis Souhami, Julio Guerra, Brenda Clark, Carole Gingras, Palma Fava
Accelerated Fractionation In Inoperable Non-Small Cell Lung Cancer. A Phase I/Ii Study, Edward Yu, Luis Souhami, Julio Guerra, Brenda Clark, Carole Gingras, Palma Fava
Edward Yu
Background: A prospective, single-treatment-arm, Phase I/II trial was performed to determine the tumor response to an accelerated regimen and assess the feasibility and toxic effects of this approach in patients with inoperable non-small cell lung cancer (NSCLC). Methods: Thirty-seven previously untreated patients with inoperable NSCLC who had no evidence of metastatic disease entered the study. All patients were able to walk and had disease that was measurable or assessable. Patients with palpable supraclavicular disease and weight loss were also eligible. Radiation therapy consisted of an altered fractionation regimen with a concomitant boost technique. The original lung volume received a dose …
The Number Of Axillary Nodes Removed As A Predictor Of Regional Recurrence In Node Negative Breast Cancer, Olga Vujovic, Edward Yu, Anil Cherian, A. Dar, Larry Stitt, Francisco Perera
The Number Of Axillary Nodes Removed As A Predictor Of Regional Recurrence In Node Negative Breast Cancer, Olga Vujovic, Edward Yu, Anil Cherian, A. Dar, Larry Stitt, Francisco Perera
Edward Yu
Purpose: To determine if the number of axillary nodes removed is a predictor of recurrence in node negative breast cancer. Materials and methods: Five hundred thirty-six patients with T1-T2, N0 invasive breast cancer, treated with lumpectomy and axillary node dissection (AND), were reviewed from January 1, 1986 to December 31, 1992. Patients received radiation to whole breast only, without regional nodal radiation. There was no adjuvant chemotherapy or Tamoxifen given. Patients were grouped according to the number of axillary nodes dissected as follows: 1-5 nodes (91 patients), 6-10 nodes (225 patients) and > 10 nodes (220 patients). Hazard ratios and p-values …
Nodal Ratios In Node-Positive Breast Cancer—Long-Term Study To Clarify Discrepancy Of Role Of Supraclavicular And Axillary Regional Radiotherapy, Patricia Tai, Kurian Joseph, Evgeny Sadikov, Shazia Mahmood, Francis Lien, Edward Yu
Nodal Ratios In Node-Positive Breast Cancer—Long-Term Study To Clarify Discrepancy Of Role Of Supraclavicular And Axillary Regional Radiotherapy, Patricia Tai, Kurian Joseph, Evgeny Sadikov, Shazia Mahmood, Francis Lien, Edward Yu
Edward Yu
Purpose: To study the absolute number of involved nodes/the number of nodes examined or the nodal ratio (NR) in breast cancer. The primary study endpoint was to evaluate the role of supraclavicular and axillary radiotherapy (SART) according to the NR. Methods and materials: From the Saskatchewan provincial registry of 1981-1995, the charts of 5,996 consecutive patients were retrieved to collect detailed prognostic factors. Among these patients, 1,985 were node positive. Because the NRs are more reliable the greater the number of nodes examined, we analyzed 1,255 patients with > or =10 nodes examined. Of these 1,255 patients, 667, 389, and 199 …
Disease-Specific Survival For Limited-Stage Small-Cell Lung Cancer Affected By Statistical Method Of Assessment, Patricia Tai, Judith-Anne Chapman, Edward Yu, Dennie Jones, Changhong Yu, Fei Yuan, Lee Sang-Joon
Disease-Specific Survival For Limited-Stage Small-Cell Lung Cancer Affected By Statistical Method Of Assessment, Patricia Tai, Judith-Anne Chapman, Edward Yu, Dennie Jones, Changhong Yu, Fei Yuan, Lee Sang-Joon
Edward Yu
Background: In general, prognosis and impact of prognostic/predictive factors are assessed with Kaplan-Meier plots and/or the Cox proportional hazard model. There might be substantive differences from the results using these models for the same patients, if different statistical methods were used, for example, Boag log-normal (cure-rate model), or log-normal survival analysis. Methods: Cohort of 244 limited-stage small-cell lung cancer patients, were accrued between 1981 and 1998, and followed to the end of 2005. The endpoint was death with or from lung cancer, for disease-specific survival (DSS). DSS at 1-, 3- and 5-years, with 95% confidence limits, are reported for all …
Long-Term Survival Rates Of Laryngeal Cancer Patients Treated By Radiation And Surgery, Radiation Alone, And Surgery Alone: Studied By Lognormal And Kaplan-Meier Survival Methods, Patricia Tai, Edward Yu, Ross Shiels, Jon Tonita
Long-Term Survival Rates Of Laryngeal Cancer Patients Treated By Radiation And Surgery, Radiation Alone, And Surgery Alone: Studied By Lognormal And Kaplan-Meier Survival Methods, Patricia Tai, Edward Yu, Ross Shiels, Jon Tonita
Edward Yu
Background: Validation of the use of the lognormal model for predicting long-term survival rates using short-term follow-up data. Methods: 907 cases of laryngeal cancer were treated from 1973-1977 by radiation and surgery (248), radiation alone (345), and surgery alone (314), in registries of Connecticut and Metropolitan Detroit of the SEER database, with known survival status up to 1999. Phase 1 of this study used the minimum chi-square test to assess the goodness of fit of the survival times of those who died with disease to a lognormal distribution. Phase 2 used the maximum likelihood method to estimate long-term survival rates …
Survival Of Patients With Metastatic Breast Cancer: Twenty-Year Data From Two Seer Registries, Patricia Tai, Edward Yu, Vincent Vinh-Hung, Gábor Cserni, Georges Vlastos
Survival Of Patients With Metastatic Breast Cancer: Twenty-Year Data From Two Seer Registries, Patricia Tai, Edward Yu, Vincent Vinh-Hung, Gábor Cserni, Georges Vlastos
Edward Yu
Background: Many researchers are interested to know if there are any improvements in recent treatment results for metastatic breast cancer in the community, especially for 10- or 15-year survival. Methods: Between 1981 and 1985, 782 and 580 female patients with metastatic breast cancer were extracted respectively from the Connecticut and San Francisco-Oakland registries of the Surveillance, Epidemiology, and End Results (SEER) database. The lognormal statistical method to estimate survival was retrospectively validated since the 15-year cause-specific survival rates could be calculated using the standard life-table actuarial method. Estimated rates were compared to the actuarial data available in 2000. Between 1991 …
Shifting From Hypofractionated To "Conventionally" Fractionated Thoracic Radiotherapy: A Single Institution's 10-Year Experience In The Management Of Limited-Stage Small-Cell Lung Cancer Using Concurrent Chemoradiation, Gregory Videtic, Pauline Truong, A. Dar, Edward Yu, Larry Stitt
Shifting From Hypofractionated To "Conventionally" Fractionated Thoracic Radiotherapy: A Single Institution's 10-Year Experience In The Management Of Limited-Stage Small-Cell Lung Cancer Using Concurrent Chemoradiation, Gregory Videtic, Pauline Truong, A. Dar, Edward Yu, Larry Stitt
Edward Yu
PURPOSE: To perform a retrospective review of a single institution's 10-year experience in treating limited-stage small-cell lung cancer (LS-SCLC) with a concurrent chemoradiation regimen modeled after the experimental arm of a randomized National Cancer Institute of Canada trial in which hypofractionated radiotherapy started with cycle 2 of chemotherapy. We then looked at the impact on patient outcomes of changing the RT during the course of the decade to a "conventionally" (2 Gy) fractionated regimen, with a focus on toxicity and survival rates. METHODS AND MATERIALS: Between 1989 and 1999, 215 LS-SCLC patients received six cycles of chemotherapy consisting of cyclophosphamide, …
Prophylactic Cranial Irradiation Revisited: Cost-Effectiveness And Quality Of Life In Small-Cell Lung Cancer, T. Tai, Edward Yu, Peter Dickof, Glen Beck, Jon Tonita, Tete Ago, David Skarsgard, Marlene Schmidt, Matthew Schmid, John Liem
Prophylactic Cranial Irradiation Revisited: Cost-Effectiveness And Quality Of Life In Small-Cell Lung Cancer, T. Tai, Edward Yu, Peter Dickof, Glen Beck, Jon Tonita, Tete Ago, David Skarsgard, Marlene Schmidt, Matthew Schmid, John Liem
Edward Yu
PURPOSE: To investigate the therapeutic usefulness and cost-effectiveness of prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer (SCLC) who had achieved a complete remission. METHODS: A retrospective chart review was undertaken of all patients diagnosed in Saskatchewan with SCLC between 1987 and 1998 inclusive. Patients who achieved a complete remission were divided into two groups, depending on whether they underwent PCI (PCI+ and PCI-, respectively). The quality-of-life-adjusted survival was estimated by the Q-TWiST method (quality time without symptoms and toxicity). The mean incremental costs per month of incremental OS were calculated in a cost-effectiveness analysis. RESULTS: Among …
Using Treatment Interruptions To Palliate The Toxicity From Concurrent Chemoradiation For Limited Small Cell Lung Cancer Decreases Survival And Disease Control, Gregory Videtic, Karen Fung, Anna Tomiak, Larry Stitt, A. Dar, Pauline Truong, Edward Yu, Mark Vincent, Walter Kocha
Using Treatment Interruptions To Palliate The Toxicity From Concurrent Chemoradiation For Limited Small Cell Lung Cancer Decreases Survival And Disease Control, Gregory Videtic, Karen Fung, Anna Tomiak, Larry Stitt, A. Dar, Pauline Truong, Edward Yu, Mark Vincent, Walter Kocha
Edward Yu
BACKGROUND AND PURPOSE: We analyzed the impact on survival outcomes of treatment interruptions due to toxicity arising during the concurrent phase of chemotherapy/radiotherapy (ChT/RT) for our limited-stage small-cell cancer (LSCLC) population over the past 10 years. MATERIALS AND METHODS: From 1989 to 1999, 215 patients received treatment for LSCLC, consisting of six cycles of alternating cyclophosphamide/doxorubicin or epirubicin/vincristine (CAV; CEV) and etoposide/cisplatin (EP). Thoracic RT was started with EP at either the second or third cycle (85% of patients). RT dose was either 40 Gy in 15 fractions over 3 weeks or 50 Gy in 25 fractions over 5 weeks, …
Practice Guideline On Prophylactic Cranial Irradiation In Small-Cell Lung Cancer, Jaro Kotalik, Edward Yu, Barbara Markman, William Evans
Practice Guideline On Prophylactic Cranial Irradiation In Small-Cell Lung Cancer, Jaro Kotalik, Edward Yu, Barbara Markman, William Evans
Edward Yu
Purpose: To develop an evidence-based clinical practice guideline that would address the following questions: (a) What is the role of prophylactic cranial irradiation (PCI) in patients with limited or extensive stage small-cell lung cancer (SCLC) who have achieved complete remission in response to induction therapy (chemotherapy or chemoradiotherapy)? (b) What dose and fractionation schedules of PCI are optimal? (c) Does the use of PCI in patients with SCLC in complete remission affect quality of life? Survival, disease-free survival, quality of life, and adverse effects were the outcomes of interest. Methods and materials: A systematic review of the published literature was …